Adjust Font Increase Font Decrease Font
  • Email
  • Print
  • RSS Feed

Media Releases

PhRMA Statement on India Supreme Court Decision on Glivec
WASHINGTON, D.C. (April 1, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani issued the following statement today: “PhRMA is very disappointed with the Indian Supreme Court’s decision to deny a patent on Glivec. This decision marks yet another example of the deteriorating innovation environment in India.  Innovation is critical in meeting unmet needs of patients and is particularly relevant in the context of changing healthcare systems. In order to solve the real health challenges of India’s patients, it is critically important that India promote a policy environment that supports continued research and development of new medicines for the health of patients in India and worldwide. Protecting intellectual...
Read more

Latest Releases

PhRMA Statement on Clinical Trials and Bad Pharma
2/4/2013
WASHINGTON, D.C. (February 4, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Executive Vice President Josie Martin issued the following statement today: “Dr. Ben Goldacre’s book Bad Pharma provides a one-sided and factually questionable view of the clinical trial processled by the innovative biopharmaceutical sector. The book ignores that the current clinical trial system, which is essential to the development of new medicines that save and improve lives, is scientifically rigorous, tightly regulated and working well.
More
Statement to Physician Payments Sunshine Act Final Rule
2/1/2013
WASHINGTON, D.C. (February 1, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today: “PhRMA is currently reviewing the final regulation of the Physician Payments Sunshine Act and looks forward to seeing how CMS addressed key concerns that were previously raised. PhRMA remains committed to the principles of the Sunshine Act and continues to believe that careful implementation is essential to ensuring that Sunshine fulfills its objective of usable, transparent, and understandable sharing of information.”
More
Pharmaceutical Organizations Announce Key Principles to Foster Supply Chain Security and Integrity
1/30/2013
Washington, D.C. (January 30, 2013) The 100th meeting of the National Conference of Pharmaceutical Organizations (NCPO) resolved that the member organizations will work together to help further secure the pharmaceutical supply chain.
More
Washington State Research Institutions Have Conducted More Than 3,600 Clinical Trials of New Medicines Since 1999
1/30/2013
Biopharmaceutical Companies Hired Them To Do The Tests
WASHINGTON, D.C. (January 29, 2013) – Working in collaboration with university medical schools and science centers, local hospitals and clinical research centers, America’s biopharmaceutical companies have conducted 3,664 clinical trials of new medicines in Washington over the last 13 years, a new study shows.
More
Rotary International and PhRMA team up for “The World’s Biggest Commercial”
1/25/2013
Leading trade group contributes $50,000 to Rotary to protect children from polio paralysis
Evanston, Ill., USA (Jan. 24, 2013) – Rotary International’s innovative campaign to develop the World’s Biggest Commercial to raise public awareness about polio eradication has struck a chord with the Pharmaceutical Research and Manufacturers of America (PhRMA).
More
Robust Biopharmaceutical Pipeline Offers New Hope for Patients
1/17/2013
Report underscores value of innovation for patients with unmet medical needs
Washington, D.C. (January 17, 2013) — The biopharmaceutical pipeline is innovative and robust, with a high proportion of potential first-in-class medicines and therapies targeting diseases with limited treatment options, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
More

Subscribe to our Email Updates